In the last two years, NMN has been the absolute "top ingredient" in the health food market and has continued to grow in popularity. After being registered in several countries, it has become popular worldwide.
However, many people still have some prejudices and misconceptions about NMN, believing it to be a chemical.
This is why the question of whether NMN is safe or not and whether there are any side effects after use has become a real concern. So this article will answer the question: "Why is NMN safe and effective?"
NMN's Latest Human Clinical Trial Results Announced
In fact, the application of any emerging active ingredient requires extensive scientific research over a long period of time to prove its safety and efficacy in humans. In fact NMN-related functional trials have already yielded a large number of positive results.
On 5 May 2022, Frontier in Aging, a leading international journal, published a report on NMN clinical trials that brings new pointers to healthy ageing.
Frontiers in Aging is one of the world's largest and most cited publishers, led and reviewed by an editorial board of over 100,000 top researchers. The trial was then reviewed by scientists, including a Harvard Medical School professor, before Frontiers in Aging agreed to publish the human clinical trial report.
This article shows that this human clinical trial, which began in 2020, has a whopping 66 participants, which is even more impressive compared to previous trials with only a dozen people.
The effect of NMN on NAD+ metabolism was investigated by measuring the effect of NMN on NAD+ metabolism. NAD+/NADH concentration, 6-minute walk endurance test, systolic blood pressure, diastolic blood pressure, pulse pressure and SF-36 questionnaire were used as study data to verify the safety and efficacy of NMN.
According to the results of the trial, serum NAD+/NADH levels, 6-minute walk endurance test, SF-36, and HOMA IR index all tended to be elevated or improved in the NMN group compared to the placebo group.
1. Serum NAD+/NADH levels
The main indicator examined to assess the effectiveness of NMN was serum NAD+/NADH levels, which were elevated by 11.3% at day 30 in the active group (NMN group) compared to basal values, while no significant change was observed in the placebo group.
At the end of the study (day 60), NAD+/NADH levels were further increased by 38% in the NMN group, compared to only 14.3% in the placebo group. In this study, the increase in the placebo group may be related to the placebo effect.
2.6 Minute Walk Endurance Test
After day 30 of the trial, there was a 4.3% increase in walking endurance in the NMN group and a 3.9% increase in the placebo group, with no effective difference observed. However, by day 60 of the trial, the NMN showed a more significant increase of 6.5%, while the placebo group remained the same, i.e. 3.9%.
It is clear from this result that the placebo effect was evident until day 30, but after that the NMN group showed further improvement in walking ability.
To examine the positive modulating effect of NMN on insulin resistance, we assessed HOMA IR index, fasting blood glucose and fasting insulin levels.
At the end of the study, the mean HOMA IR index increased by 0.6% from baseline in the NMN group and by 30.6% in the placebo group. Mean fasting glucose levels decreased by 4.0% in the NMN group and increased by 6.5% in the placebo group. mean fasting insulin levels decreased by 1.9% in the NMN group and increased by 26.2% in the placebo group.
This data shows that the NMN supplementation group can keep fasting blood glucose and insulin levels at a relatively stable state.
The SF-36 questionnaire score reflects the subject's health status. The higher the score, the better the health status of the subject and the higher the well-being index.
At day 30 after the start of the trial, scores in the NMN group improved by 4.0% compared to 3.7% in the placebo group. Therefore no significant difference was observed. However, on day 60, the NMN group increased by 6.5% compared to 3.4% for the placebo group, almost twice the rate of increase for the NMN group.
During the course of this trial after 60 days, the subjects were supplemented with 300 mg of NMN daily, in which there were no significant changes in any of the baseline physiological parameters (blood analysis, liver and kidney function, systolic blood pressure, diastolic blood pressure, pulse pressure, etc.), which fully demonstrates the safety of NMN supplementation under the test conditions.
In fact, as an endogenous compound, NMN is a slow and gradual process that regulates all physiological functions in the human body. The above test results fully demonstrate the potential of NMN supplementation to improve human vitality and prove that NMN is safe to consume.